H

Huakang Biomedical Holdings Co Ltd
HKEX:8622

Watchlist Manager
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Watchlist
Price: 0.176 HKD 7.32%
Market Cap: 88.1m HKD
Have any thoughts about
Huakang Biomedical Holdings Co Ltd?
Write Note

Huakang Biomedical Holdings Co Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Huakang Biomedical Holdings Co Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
H
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Total Liabilities & Equity
ÂĄ65.3m
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
K
Kaisa Health Group Holdings Ltd
HKEX:876
Total Liabilities & Equity
HK$567.7m
CAGR 3-Years
-15%
CAGR 5-Years
-12%
CAGR 10-Years
8%
K
Kelfred Holdings Ltd
HKEX:1134
Total Liabilities & Equity
HK$264m
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Arts Optical International Holdings Ltd
HKEX:1120
Total Liabilities & Equity
HK$1.2B
CAGR 3-Years
6%
CAGR 5-Years
-3%
CAGR 10-Years
-3%
O
OrbusNeich Medical Group Holdings Ltd
HKEX:6929
Total Liabilities & Equity
$410.1m
CAGR 3-Years
58%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Huakang Biomedical Holdings Co Ltd
Glance View

Market Cap
88.1m HKD
Industry
Health Care

Huakang Biomedical Holdings Co. Ltd. operates as a medical group company. The company employs 83 full-time employees The company went IPO on 2018-12-13. The IVD reagents include male fertility IVD reagents, Epstein-Barr virus antibody detection reagents ad parasite antibody detection reagents, among others. The male fertility IVD reagents include sperm function test products, accessory genital glands test products, anti-sperm antibody test products, as well as male reproductive tract infection test products, among others. In addition, the Company is also involved in the sale of auxiliary reproductive supplies and equipments, such as glass coverslips and sperm sample collection cups.

Intrinsic Value
0.085 HKD
Overvaluation 52%
Intrinsic Value
Price
H

See Also

What is Huakang Biomedical Holdings Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
65.3m CNY

Based on the financial report for Dec 31, 2023, Huakang Biomedical Holdings Co Ltd's Total Liabilities & Equity amounts to 65.3m CNY.

What is Huakang Biomedical Holdings Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-5%

Over the last year, the Total Liabilities & Equity growth was -2%. The average annual Total Liabilities & Equity growth rates for Huakang Biomedical Holdings Co Ltd have been -4% over the past three years , -5% over the past five years .

Back to Top